沙利度胺对AnnexinⅡ基因的调节作用

目的 了解沙利度胺在体外对人多发性骨髓瘤(MM)细胞系RPMI8226、人微血管内皮细胞系HMEC-1中Annexin Ⅱ(AnxA2)基因表达的调节作用,探讨沙利度胺诱发血栓的可能机制.方法 实时荧光定量PCR检测在不同浓度下沙利度胺对两种细胞系AnxA2 mRNA表达的影响,采用流式细胞术、激光共聚焦仪检测不同浓度下沙利度胺对细胞膜表面AnxA2蛋白表达的影响.结果 当沙利度胺浓度为12.5、25.0、50.0 μg/ml时,RPMl8226细胞AnxA2 mRNA表达水平为0.60±0.15、0.33±0.14、0.42±0.16,较对照组(1.07±0.16)降低(P<0.05),HMEC-1细胞AnxA2 mRNA表达水平为0.21±0.20、0.08 ±0.08、0.17±0.16,较对照组(1.16 ±0.24)降低(P<0.05).沙利度胺浓度为12.5、25.0、50.0 μg/ml时,RPMI8226细胞膜表面AnxA2蛋白表达水平为3.39±0.32、2.82 ±0.28、3.21 ±0.23,较对照组(5.53 ±0.32)降低(P<0.05),HMEC-1细胞膜表面AnxA2蛋白表达水平为0.72 ±0.11、0.64 ±0.08、0.67±0.08,较对照组(1.40±0.15)降低(P<0.05).结论 沙利度胺能抑制RPMI8226和HMEC-1细胞AnxA2 mRNA和蛋白表达,可能为其诱发骨髓瘤血栓形成的原因之一.     

胰岛素样生长因子Ⅰ抑制氧化型低密度脂蛋白诱导内皮细胞凋亡的体外试验

目的：胰岛素样生长因子Ⅰ作为重要的促细胞生长因子之一，其对内皮细胞凋亡影响的报道不多。实验拟验证和探讨胰岛素样生长因子Ⅰ对氧化型低密度脂蛋白诱导人脐静脉内皮细胞凋亡的抑制作用及可能机制。 方法：实验于2006—12／2007—07在华中科技大学同济医学院协和医院心血管疾病研究所完成。①实验材料及分组处理：取人新鲜脐带（产妇或家属签署知情同意书）分离培养人脐静脉内皮细胞，分为：胰岛素样生长因子Ⅰ组（1×10^-9mmol／L）、氧化型低密度脂蛋白（200mg／L）＋胰岛素样生长因子Ⅰ组（1×10^-9mmol／L）、氧化型低密度脂蛋白（200mg／L）组、正常对照组。分别在细胞培养24h后加入。②实验评估：采用四甲基偶氮唑盐法测定细胞活力；DAPI细胞核荧光染色法观察细胞凋亡的形态学变化及细胞凋亡率的测定；并进行内皮细胞caspase-3活性的检测。 结果：①氧化型低密度脂蛋白可明显抑制人脐静脉内皮细胞增殖，胰岛素样生长因子Ⅰ与氧化型低密度脂蛋白共同加入后，细胞增殖率明显上升（P〈0．05）。②氧化型低密度脂蛋白可诱导人脐静脉内皮细胞发生凋亡，而加入胰岛素样生长因子I刺激后细胞凋亡率降低（P〈0．05）。③caspase-3活性检测表明与对照组相比，氧化型低密度脂蛋白能明显上调caspase-3的表达，而胰岛素样生长因子Ⅰ＋氧化型低密度脂蛋白组caspase-3活性则降低（P〈0．05）。 结论：胰岛素样生长因子Ⅰ对氧化型低密度脂蛋白诱导的人脐静脉内皮细胞凋亡具有抑制作用，可能与其下调caspase-3蛋白表达有关。     

Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway

Although chemotherapy treatment is associated with an increased risk of thrombosis, the pathogenic mechanisms for the thrombogenic effect of chemotherapeutic drugs are poorly understood. We hypothesize that exposure of vascular endothelial cells to chemotherapeutic agents results in the loss of a thromboresistant phenotype. In this study, we examined the effects of the chemotherapeutic agent doxorubicin on the endothelium-based protein C anticoagulant pathway. The endothelial cell protein C receptor (EPCR) and thrombomodulin are two endothelial cell surface receptors required for the conversion of zymogen protein C to the anticoagulant enzyme activated protein C. Exposure of human umbilical vein endothelial cells (HUVEC) to doxorubicin resulted in a dose- and time-dependent decrease in cell surface EPCR levels. This decrease occurred as a result of receptor shedding as well as from a down-regulation in EPCR mRNA levels. In contrast, doxorubicin treatment of HUVECs resulted in a dose- and time-dependent increase in cell surface thrombomodulin attributed to an up-regulation of thrombomodulin mRNA levels. The net effect of the doxorubicin-induced changes in EPCR and thrombomodulin levels was a decrease in the capacity of HUVECs to convert protein C to activated protein C. Preliminary studies suggest that doxorubicin free radical metabolites mediate the doxorubicin-induced changes in EPCR expression but not those of thrombomodulin expression. In summary, these results suggest that doxorubicin alters the hemostatic balance of endothelial cells by down-regulating the endothelium-based protein C anticoagulant pathway.     

酞咪哌啶酮对多发性骨髓瘤细胞系血管新生抑制作用的研究

目的 研究多发性骨髓瘤（MM）细胞系培养上清液对人骨髓来源的内皮细胞系（HBMEC）的增殖，迁移，血管新生的促进作用及酞咪哌啶酮对其抑制作用。方法 用MM细胞系（IM9，XG1，U266和MOLP-5）培养上清液培养HBMEC，检测其对HBMEC的增殖，迁移作用，在纤维蛋白胶及基质胶（matrigel)中观察此上清液对血管新生的影响，并研究酞咪哌啶酮对这些作用的抑制。用酶联免疫吸附实验（ELISA）测定此上清液中血管内皮生长因子（VEGF）含量。结果 MM培养上清液明显促进HBMEC的增殖及迁移，在纤维蛋白胶及基质胶（matrigel)中，促进微血管的生长。这些作用均可被酞咪哌啶酮抑制。所有这些作用与MM细胞系产生的VEGF无相关性。结论 MM细胞系通过分泌VEGF或其他某些细胞因子促进HBMEC的增殖，迁移及微血管形成；酞咪哌啶酮可抑制这些作用。并可作为MM的临床治疗方法之一。     

Blockade of angiogenin by thalidomide inhibits the tumorigenesis of murine hemangioendothelioma

Thalidomide, a well‐known immunomodulatory compound, has an anti‐angiogenic activity, which may be utilized for the treatment of angiogenesis‐related diseases such as hemangioendothelioma. The aim of the present study was to investigate both the antitumor role of thalidomide on hemangioendothelioma and the underlying mechanism. By using the xenograft mouse model, we found that thalidomide can inhibit the progression of hemangioendothelioma in vivo. Moreover, thalidomide shows no effect on the proliferation of hemangioendothelioma endothelial cell (EOMA), but significantly impairs the pro‐angiogenic capacity of the EOMA cells in vitro. By qRT‐PCR screening, we observed that the expression of angiogenin was downregulated by thalidomide treatment. We next performed tissue array analysis and found a positive correlation between angiogenin expression level and hemangioendothelioma occurrence in patients. Moreover, we confirmed that the antitumoral role of thalidomide is dependent on angiogenin expression both in vivo and in vitro. Taken together, we concluded that thalidomide can inhibit the progression of hemangioendothelioma by downregulating the expression of pro‐angiogenic factor angiogenin and therefore can be used as a potent therapeutic to treat hemangioendothelioma.     

Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine.

Elevated levels of plasma homocysteine are associated with both venous and arterial thrombosis. Homocysteine inhibits the function of thrombomodulin, an anticoagulant glycoprotein on the endothelial surface that serves as a cofactor for the activation of protein C by thrombin. The effects of homocysteine on thrombomodulin expression and protein C activation were investigated in cultured human umbilical vein endothelial cells and CV-1(18A) cells that express recombinant human thrombomodulin. Addition of 5 mM homocysteine to endothelial cells produced slight increases in thrombomodulin mRNA and thrombomodulin synthesis without affecting cell viability. In both cell types, thrombomodulin synthesized in the presence of homocysteine remained sensitive to digestion with endoglycosidase H and failed to appear on the cell surface, suggesting impaired transit along the secretory pathway. In a cell-free protein C activation assay, homocysteine irreversibly inactivated both thrombomodulin and protein C in a process that required free thiol groups and was inhibited by the oxidizing agents diamide or N-ethylmaleimide. By inhibiting both thrombomodulin surface expression and protein C activation, homocysteine may contribute to the development of thrombosis in patients with cystathionine beta-synthase deficiency.     

Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells

Endothelial progenitor cells (EPCs) from the bone marrow play an important role in vascular response to injury and ischemia. The mediators involved in the mobilization, recruitment, proliferation and differentiation of EPCs are not fully understood. In this study, the role of coagulation factor thrombin and protease-activated receptor-1 (PAR-1) on bone marrow-derived cell proliferation and differentiation was investigated. Bone marrow cells (BMCs) were isolated from C57/BL6 mice and plated on fibronectin-coated flasks. Cell characteristics, proliferation and the expression of endothelial cell markers were determined using immunohistochemistry, thymidine uptake and fluorescence activated-cell sorting (FACS), respectively. The results show that thrombin stimulated enrichment of bone marrow cells with endothelial morphology, exhibiting acetylated-low-density lipoprotein (LDL) uptake and isolectin staining. Thrombin or PAR-1-activating peptide produced a 2- to 3-fold increase in the total number of cells as well as an increase in vascular endothelial (VE)-cadherin-positive cells. Thrombin treatment of VE-cadherin-negative cells prepared after cell sorting resulted in the generation of 3- to 4-fold higher VE-cadherin-positive cells than the untreated cultures. Increase in VE-cadherin-positive cells was inhibited by hirudin and efegatran. These results provide first evidence for a novel activity of thrombin and PAR-1 on bone marrow progenitor cell proliferation and EPC differentiation, and suggest their potential role in vascular regeneration and recanalization of thrombus.     

Cytosine arabinoside induces programmed endothelial cell death through the caspase-3 pathway

The anti-cancer effects of cytosine arabinoside (ARA-C) are well known. However, effects on nonmalignant cells have not been elucidated and may be important to understanding treatment-related toxicity. The purpose of this study was to examine the effect of ARA-C on nondividing vascular endothelial cells. The objectives were to determine the effects of ARA-C on cell viability and to ascertain whether ARA-C caused apoptosis in cultured vascular endothelial cells and hydrocortisone blunted caspase-3-induced apoptosis. Endothelial cells were cultured until confluent and mitotically quiescent then exposed to ARA-C (10(-7)to 10(-3) M) for 1 to 4 days. Some experiments involved cotreatment with hydrocortisone (10(-11),10(-10),10(-4), and 10(-3) M). Light microscopy and the colorimetric MTS assay were used to measure viability. Fluorescent annexin-V and DNA fragmentation assays were used to measure apoptosis, and a fluorescence-based enzymatic assay was used to measure caspase-3 activity, which is one pathway involved in the apoptosis cascade. Two-way ANOVA or the appropriate nonparametric test was used to determine statistical significance in studies of viability and apoptosis. Oneway ANOVA was used to determine statistical significance for caspase-3 activity. Viability was decreased with higher concentrations of ARA-C and increased days of treatment. The percentage of apoptotic cells increased with higher concentrations of ARA-C and increased days of treatment. ARA-C-treated samples showed DNA fragmentation, indicative of apoptosis. Caspase-3 activity increased after ARA-C addition; hydrocortisone blunted this increase. ARA-C caused apoptosis in nondividing endothelial cells in culture. Hydrocortisone may protect against ARA-C-induced apoptosis by reducing caspase-3 activity.     

A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-alpha inhibitor

Dose-limiting diarrhea and myelosuppression compromise the success of irinotecan (7-ethyl-10-[4-[1-piperidino]-1-piperidino]carbonyloxycamptothecin) (CPT-11)-based chemotherapy. A recent pilot study indicates that thalidomide attenuates the toxicity of CPT-11 in cancer patients. This study aimed to investigate whether coadministered thalidomide modulated the toxicities of CPT-11 and the underlying mechanisms using several in vivo and in vitro models. Diarrhea, intestinal lesions, cytokine expression, and intestinal epithelial apoptosis were monitored. Coadministered thalidomide (100 mg/kg i.p. for 8 days) significantly attenuated body weight loss, myelosuppression, diarrhea, and intestinal histological lesions caused by CPT-11 (60 mg/kg i.v. for 4 days). This was accompanied by inhibition of tumor necrosis factor-alpha, interleukins 1 and 6 and interferon-gamma, and intestinal epithelial apoptosis. Coadministered thalidomide also significantly increased the systemic exposure of CPT-11 but decreased that of SN-38 (7-ethyl-10-hydroxycampothecin). It significantly reduced the biliary excretion and cecal exposure of CPT-11, SN-38, and SN-38 glucuronide. Thalidomide hydrolytic products inhibited hydrolysis of CPT-11 in rat liver microsomes but not in primary rat hepatocytes. In addition, thalidomide and its major hydrolytic products, such as phthaloyl glutamic acid (PGA), increased the intracellular accumulation of CPT-11 and SN-38 in primary rat hepatocytes. They also significantly decreased the transport of CPT-11 and SN-38 in Caco-2 and parental MDCKII cells. Thalidomide and PGA also significantly inhibited P-glycoprotein (PgP/MDR1), multidrug resistance-associated protein (MRP1)- and MRP2-mediated CPT-11 and SN-38 transport in MDCKII cells. These results provide insights into the pharmacodynamic and pharmacokinetic mechanisms for the protective effects of thalidomide against CPT-11-induced intestinal toxicity.     

Breast cancer chemotherapy induces the release of cell‐free DNA,a novel procoagulant stimulus

See also van den Berg YW, Reitsma PH. Not exclusively tissue factor: neutrophil extracellular traps provide another link between chemotherapy and thrombosis. This issue, pp 2311–2. Summary. Background: Thrombosis is a common complication for breast cancer patients receiving chemotherapy. However, the mechanisms by which breast cancer chemotherapeutic agents increase this risk are largely uncharacterized. Nucleic acids released by injured cells may enhance coagulation via the activation of the contact pathway. Objectives: In this study, we examined the effects of breast cancer chemotherapy agents on the release of cell‐free DNA (CFDNA) and its relationship to thrombin generation using in vitro and in vivo methods. Methods: CFDNA release and thrombin‐antithrombin (TAT) levels were measured in plasma of breast cancer patients and healthy mice receiving chemotherapy. Venous whole blood and cultured cells were exposed to chemotherapy and CFDNA release and levels of DNA‐histone complexes were measured. The procoagulant activity of isolated CFDNA was measured with calibrated, automated thrombin generation. Results: Breast cancer patients receiving chemotherapy had elevated levels of CFDNA 24 h post‐chemotherapy, a time‐point at which elevated thrombin‐antithrombin levels have been previously reported. Treatment of healthy mice with doxorubicin, epirubicin and 5‐fluorouracil increased CFDNA release, with a corresponding elevation in TAT complex formation. Venous whole blood and neutrophils incubated with chemotherapeutic agents had elevated CFDNA in plasma or cell supernatants. In addition, incubation of venous whole blood with chemotherapy decreased histone‐DNA complex levels. CFDNA released from epirubicin‐treated whole blood significantly elevated thrombin generation in a dose‐dependent manner, and involved activation of the contact pathway. Conclusions: Release of CFDNA from chemotherapy‐injured cells may represent a novel mechanism by which thrombosis is triggered in cancer patients.     

沙利度胺对类风湿关节炎滑膜成纤维样细胞影响的体外研究

目的研究沙利度胺(Thalidomide)对类风湿关节炎(RA)滑膜成纤维样细胞(FLS)体外培养时的增生殖分化特性的影响。方法关节镜、关节活检针取RA患者滑膜组织,分离培养和鉴定FLS,MTT法和反转录-聚合酶链反应(RT-PCR)方法观察沙利度胺对FLS细胞存活分数(SF)和c-fos、COX-2mRNA表达。结果RA-FLS体外培养呈良性增生。沙利度胺对RA-FLS的SF值的抑制作用最强(P<0.05)。生理剂量的沙利度胺干预时的浓度与FLS的SF值呈负相关。RA-FLS的c-fos、环氧化酶2(COX-2)mRNA表达率高,加入沙利度胺共孵育3天后c-fos和COX-2mRNA的表达率均明显下降。结论培养和鉴定RA滑膜细胞,证实体外培养传代的RA-FLS为非恶性无限制增生。实验剂量下沙利度胺通过抑制c-fos、COX-2的表达、降低FLS增殖能力等不同途径,发挥对RA滑膜细胞的免疫调节作用。     

Methotrexate causes apoptosis in postmitotic endothelial cells

Methotrexate (MTX) is a commonly used chemotherapy agent for a variety of cancers. However, therapeutic levels are associated with numerous untoward effects such as central nervous system damage in children with acute lymphoblastic leukemia. The purpose of this study was to determine if MTX caused injury to endothelial cells using cultured bovine pulmonary artery endothelial cells as a model. Light microscopy showed gaps between cells and reduced numbers of endothelial cells after exposure to MTX (10(-9) to 10(-5) M), a range consistent with therapeutic drug levels. Proliferation and viability of subconfluent and confluent MTX-treated endothelial cells were measured by colorimetric (MTS) assay. There was a significant decline in cell numbers in MTX-treated subconfluent (growing) cells cultured after 4 days of MTX exposure compared to controls, as expected. However, there was also an unexpected decline in cell numbers in MTX-treated postmitotic endothelial cells after 1, 3, and 4 days of drug exposure. This suggested that MTX induced endothelial cell death. Fluorescent ApoAlert Enhanced Annexin-V binding demonstrated apoptosis in endothelial cells after 1 day of MTX exposure. Apoptosis was confirmed by a DNA fragment assay. This is apparently the first report of MTX-induced apoptosis of postmitotic, cultured endothelial cells. The findings suggest that apoptosis may be one mechanism of MTX-induced injury to endothelial cells.     

Ⅰ型磷酸酶抑制亚基1对大鼠心肌细胞缺氧/复氧损伤的保护作用

目的 探讨Ⅰ型磷酸酶抑制亚基1(PPI1)对大鼠乳鼠心肌细胞缺氧/复氧(H/R)损伤的保护作用及其机制.方法 用PPI1野生型和活化型突变体表达质粒分别转染乳鼠心肌细胞,并建立乳鼠心肌细胞缺氧/复氧H/R模型,测定各组心肌细胞的存活率、丙二醛(MDA)、乳酸脱氢酶(LDH)的含量、caspase-3活性及超氧化物歧化酶(SOD)活力,此外用流式细胞术测定各组心肌细胞凋亡率,Western blot分析PPI1对凋亡相关蛋白表达及PI3K/Akt信号通路的影响.结果 与正常组比较,模型组LDH、MDA含量、caspase-3活性及细胞凋亡率增高(P<0.05),细胞存活率和SOD活性降低(P<0.05);PPI1活化型突变体转染组细胞的LDH、MDA含量、caspase-3活性和细胞凋亡率则降低,细胞存活率和SOD活性升高,与缺氧/复氧组比较各实验指标差异均具有统计学意义(P<0.05).Western blot表明该组细胞P53、Bax 表达下调,pAkt表达上调.结论 PPI1活化型突变体对H/R造成的心肌细胞损伤具有保护作用,其机制与稳定心肌细胞膜、减轻氧自由基损伤及减少细胞凋亡有关.     

Lack of In Vitro Antimicrosporidian Activity of Thalidomide

Thalidomide was evaluated for its in vitro activity against Encephalitozoon species by using the MRC-5 cell system. A cytotoxic effect was observed for concentrations of 10(1) microg/ml (P < 10(5)) and 5 microg/ml (P < 10(5)). Thalidomide did not significantly inhibit the growth of any of the microsporidia under study. These data suggest that thalidomide is not an etiologic treatment in microsporidial enteritis.     

Differential effects of alliin and allicin on apoptosis and senescence in luminal A and triple-negative breast cancer: Caspase, ΔΨm,and pro-apoptotic gene involvement

Breast cancer is the most frequent cancer in women worldwide, and drug resistance is common in all breast cancer types. The combination of natural products with chemotherapies has attracted attention, as it was found that natural compounds enhance the effects of standard cancer chemotherapeutic drugs and protect from side effects. Into the different natural products, garlic has been recognized for its antitumor properties. It is suggested that its anticancer effects are associated with its organo-sulfur compounds, especially alliin and allicin. Here, we evaluated the effects of both molecules on cell death, senescence, and their senolytic potential in luminal A and triple-negative breast cancer cells. MCF-7 (luminal A) and HCC-70 (triple-negative) cells were cultured and treated with different concentrations of alliin or allicin. Then, cell viability was determined using the WST-1 reagent. Apoptosis and caspase activity were evaluated by flow cytometry; ΔΨm was assessed using a JC-10 fluorometric assay kit. Apoptosis-related genes were evaluated by RT-PCR. Proliferation was measured using bromodeoxyuridine incorporation. We also evaluated clonogenicity, senescence (β-Galactosidase Staining), and the senolytic effect of the compounds. Our results showed that allicin has antiproliferative, anticlonogenic, and senolytic effects. In addition, allicin decreased cell viability and induced apoptosis by loss of ΔΨm, caspase-3, caspase-8, and caspase-9 activation, upregulation of NOXA, P21, and BAK, as well as downregulation of BCL-XL expression. Contrary to allicin, alliin promoted clonogenicity, induced senescence, and did not exhibit pro-apoptotic effects in breast cancer cells.     

Thalidomide in cancer.

Thalidomide has immunomodulatory and anti-angiogenic properties which may underlie its activity in cancer. After its success in myeloma, it has been investigated in other plasma cell dyscrasias, myelodysplastic syndromes, gliomas, Kaposi's sarcoma, renal cell carcinoma, advanced breast cancer, and colon cancer. Thalidomide causes responses in 30-50% of myeloma patients as a single agent, and acts synergistically with corticosteroids and chemotherapy. Thalidomide results in the reduction or elimination of transfusion-dependence in some patients with myelodysplastic syndrome. Responses have also been seen in one-third of patients with Kaposi's sarcoma, in a small proportion of patients with renal cell carcinoma and high-grade glioma, and in some patients with colon cancer in combination with irinotecan. The drug is being investigated currently in a number of clinical trials for cancer. Drowsiness, constipation, and fatigue are common side effects, whereas peripheral neuropathy and skin rash are seen in one-third. A minority of patients experience bradycardia. Thrombotic phenomena are especially common when thalidomide is combined with chemotherapy. Adverse effects severe enough to necessitate cessation of therapy are seen in around 20% of patients. A therapeutic trial of thalidomide is essential in all patients with relapsed or refractory myeloma. In other cancers, the best way to use the drug is in the setting of clinical trials. In the absence of access to studies or alternative therapeutic options, thalidomide could be considered singly or in combination with standard therapy.     

沙利度胺对白血病细胞NKG2D配体表达及NK细胞杀伤敏感性的影响

目的:探究沙利度胺对白血病细胞自然杀伤细胞及活性受体D(natural killer cell group 2 member D,NKG2D)配体表达及自然杀伤细胞(natural killer,NK)杀伤敏感性的影响。方法:取对数生长期白血病细胞株HL-60、K562细胞,以不同浓度沙利度胺作用48h,并设置未经沙利度胺处理的细胞为对照组,采用细胞计数实验(cell counting kit-8,CCK-8)检测沙利度胺对细胞的半抑制浓度(half-inhibitory concentration,IC50),实时荧光定量聚合酶链反应(real-time fluorescence quantitative polymerase chain reaction,RT-PCR)和流式细胞术检测细胞NKG2D配体[MHC-I类链相关分子A(major histocompatibility complex classⅠchain-related protein A,MICA)、MICB]及人巨细胞病毒UL16蛋白的结合蛋白[(UL16-binding proteins,ULBPs:ULBP1、ULBP2、ULBP3)]表达情况,乳酸脱氢酶(lactate dehydrogenase,LDH)释放法检测沙利度胺对NK-92MI细胞的杀伤效率。结果:沙利度胺干预HL-60、K562细胞,IC50分别为30.06、31.95μg/mL,且随着沙利度胺浓度的升高,抑制作用越明显;与对照组比较,沙利度胺组MICB、ULBP1、ULBP2基因mRNA水平明显升高(P<0.05),但MICA和ULBP3 mRNA水平无明显变化(P>0.05);与对照组比较,沙利度胺组MICB、ULBP1、ULBP2表达明显升高(P<0.05),但MICA和ULBP3表达无明显变化(P>0.05);效靶比分别为1:1、5:1、10:1时,与对照组比较,沙利度胺组NK-92MI对细胞的杀伤效率明显升高(P<0.05)。结论:沙利度胺可能通过提高NKG2D配体MICB、ULBP1、ULBP2表达,提高HL-60、K562细胞对NK-92MI的杀伤敏感性。